Discovery of new anticancer agents from higher plants

Frontiers in Bioscience - Scholar

Volumn 4 S, Issue 1, 2012, Pages 142-156

  Pan, Li ^a   Chai, Hee Byung ^a   Kinghorn, Alan Douglas ^a  

^a OHIO STATE UNIVERSITY   (United States)

Author keywords

Antineoplastic activity; Clinically used anticancer drugs; Compounds in clinical trials; Experimental agents; Plants; Review

Indexed keywords

2'' DEOXY 2'' (DIMETHYLAMINO)ETOPOSIDE; ALKALOID DERIVATIVE; ANTINEOPLASTIC AGENT; BETULIC ACID; CAMPTOTHECIN; COMBRETASTATIN A4; CURCUMIN; DITERPENOID; EPIPODOPHYLLOTOXIN; FLAVOPIRIDOL; HOMOHARRINGTONINE; INDIRUBIN; LAROTAXEL; LYCOPENE; OMBRABULIN; PACLITAXEL; PACLITAXEL POLIGLUMEX; PERILLYL ALCOHOL; PODOPHYLLOTOXIN; PROTOPANAXADIOL; QUASSINOID; QUINOLINE; RESVERATROL; RUBITECAN; SILVESTROL; TAFLUPOSIDE; TANSHINONE I; UNCLASSIFIED DRUG; VINBLASTINE; VINCA ALKALOID; VINCRISTINE; BIOLOGICAL PRODUCT; PLANT EXTRACT;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CHEMOTHERAPY; CYTOTOXICITY; DRUG DESIGN; DRUG MECHANISM; DRUG STRUCTURE; HEAD AND NECK CANCER; LEUKEMIA; LYMPHOMA; MELANOMA; PROSTATE CANCER; VASCULAR PLANT; ANIMAL; CHEMISTRY; CLINICAL TRIAL (TOPIC); HUMAN; PLANT; REVIEW;

EMBRYOPHYTA;

ANIMALS; ANTINEOPLASTIC AGENTS, PHYTOGENIC; BIOLOGICAL AGENTS; CLINICAL TRIALS AS TOPIC; HUMANS; PLANT EXTRACTS; PLANTS;

EID: 84860122062     PISSN: 19450516     EISSN: 19450524     Source Type: Journal    
DOI: 10.2741/257     Document Type: Article

References (125)

1. Ka. U. Bindseil, Jasmi. Jakupovica, Dietma. Wolf, Jacque. Lavayre, Jean Leboul and Didier van der Pyl: Pure compound libraries: a new perspective for natural product based drug discovery. Drug. Discov. Today 6, 840-847 (2001) (Pubitemid 32734512)
2. Richard D. Firn and Clive G. Jones: Natural products - a simple model to explain chemical diversity. Nat. Prod. Rep. 20, 382-391 (2003) (Pubitemid 37007962)
3. P. Vuorela, M. Leinonen, P. Saikku, P. Tammela, J.-P. Rauha, T. Wennberg and H. Vuorela: Natural products in the process of finding new drug candidates. Curr. Med. Chem. 11, 1375-1389 (2004) (Pubitemid 38735784)
4. David J. Newman and Gordon M. Cragg: Natural products as sources of new drugs over the last 25 years. J. Nat. Prod. 70, 461-477 (2007) (Pubitemid 46595760)
5. Fran. E. Koehn, Guy T. Carter: The evolving role of natural products in drug discovery. Nature Rev. Drug Disc. 4, 206-220 (2005) (Pubitemid 40372555)
6. Kin S. Lam: New aspects of natural products in drug discovery. Trends Microbiol. 15, 279-289 (2007) (Pubitemid 46856162)
7. Jess. W.-H. Li, John C. Vederas: Drug discovery and natural products: end of an era or an endless frontier? Science 325, 161-165 (2009)
8. Christian Bailly: Ready for a comeback of natural products in oncology. Biochem. Pharmacol. 77, 1447-1457 (2009)
9. Arvin. Saklani, Samuel K. Kutty: Plant-derived compounds in clinical trials. Drug Disc. Today 13, 161-171 (2008)
10. Alan L. Harvey: Natural products in drug discovery. Drug Disc. Today 13, 894-901 (2008).
11. Mark S. Butler: Natural products to drugs: natural product-derived compounds in clinical trials. Nat. Prod. Rep. 25, 475-516 (2008) (Pubitemid 351725315)
12. R. H. Noble, J. H. Cutts, C. H. Beer: Further biological activities of vincaleukoblastine - an alkaloid isolated from Vinca rosea (L.). Biochem. Pharmacol. 1347-1348 (1958)
13. Norber. Neuss, Marvi. Gorman, Harol. E. Boaz, Nancy J. Cone: Vinca alkaloids. XI. Structures of leurocristine and vincaleukoblastine. J. Am. Chem. Soc. 84, 1509-1510 (1962)
14. Gordon H. Svoboda: Alkaloids of Vinca rosea (Catharanthus roseus). IX. Extraction and characterization of leurosidine and leurocristine. Lloydia 24, 173-178 (1961)
15. Jonatha. L. Hartwell, Anthony W. Schrecker: Components of podophyllin. V. The constitution of podophyllotoxin. J. Am. Chem. Soc. 73, 2909-2916 (1951)
16. Mansuk. C. Wani, Harol. Lawrence Taylor, Monro. E. Wall, Phili. Coggon, Andrew T. McPhail: Plant antitumor agents. VI. Isolation and structure of taxol, a novel antileukemic and antitumor agent from Taxus brevifolia. J. Am. Chem. Soc. 93, 2325-2327 (1971)
17. Monro. E. Wall, M. C. Wani, C. E. Cook, Keit. H. Palmer, A. T. McPhail, G. A. Sim: Plant antitumor agents. I. The isolation and structure of camptothecin, a novel alkaloidal leukemia and tumor inhibitor from Camptotheca acuminata. J. Am. Chem. Soc. 88, 3888-3890 (1966)
18. Mar. Ann Jordan, Leslie Wilson: Microtubules as a target for anticancer drugs. Nat. Rev. 4, 253-265 (2004) (Pubitemid 38525281)
19. David G. I. Kingston: Tubulin-interactive natural products as anticancer agents. J. Nat. Prod. 72, 507-515 (2009).
20. Gordo. M. Cragg, David J. Newman: A tale of two tumor targets: topoisomerase I and tubulin. the Wall and Wani contribution to cancer chemotherapy. J. Nat. Prod. 67, 232-244 (2004) (Pubitemid 38282915)
21. Yaw-Hue. Hsiang, Michell. G Lihou, Leroy F. Liu: Arrest of replication forks by drug-stabilized topoisomerase I-DNA cleavable complex as a mechanism of cell killing by camptochecin. Cancer. Res. 49, 5077-5082 (1989) (Pubitemid 19239347)
22. K. R. Hande: Etoposide: four decades of development of a topoisomerase II inhibitor. Eur. J. Cancer 34, 1514-1521 (1998) (Pubitemid 28446331)
23. Gordo. M. Cragg, Davi. G. I. Kingston, Davi. J. Newman, Eds.: Anticancer Agents from Natural Products, CRC/Taylor & Francis, Boca Raton, FL (2005)
24. M. Gordaliza: Natural products as leads to anticancer drugs. Clin. Transl. Oncol. 9, 767-776 (2007).
25. Gordo. M. Cragg, Pau. G. Grothaus, David J. Newman: Impact on natural products on developing new anticancer agents. Chem. Rev. 109, 3012-3043 (2009).
26. Matthe. Suffness, John Douros: Current status of the NCI plant and animal program. J. Nat. Prod. 45, 1-14 (1982)
27. Gordo. M. Cragg, Michae. R. Boyd, Rit. Khanna, Rober. Kneller, Thoma. D. Mays, Kat. D. Mazan, Davi. J. Newman, Edward A. Sausville: International collaboration in drug discovery and development: the NCI experience. Pure Appl. Chem. 71, 1619-1633 (1999)
28. Gordo. M. Cragg, Davi. J. Newman, Stringner S. Yang: Natural product extracts of plant and marine origin having antileukemia potential. The NCI experience. J. Nat. Prod. 69, 488-498 (2006)
29. Yal. F. Hallock, Gordon M. Cragg: National Cooperative Drug Discovery Groups (NCDDGs): a successful model for public private partnerships in cancer drug discovery. Pharm. Biol. 41(Suppl.), 78-91 (2003) (Pubitemid 39564235)
30. Melind. G. Hollingshead, Michae. C. Alley, Richar. F. Camalier, Bett. J. Abbott, Josep. G. Mayo, Loui. Malspeis, Michael R. Grever: In vivo cultivation of tumor cells in hollow fibers. Life Sci. 57, 131-141 (1995).
31. Qiuwe. Mi, Joh. M. Pezzuto, Norma. R. Farnsworth, Mansuk. C. Wani, A. Douglas Kinghorn, Steven M. Swanson: Use of the in vivo hollow fiber assay in natural products drug discovery. J. Nat. Prod. 72, 573-580 (2009)
32. Emil. Pisha, Heebyun. Chai, Ik-So. Lee, Tanga. E. Chagwedera, Norma. R. Farnsworth, Geoffre. A. Cordell, Christophe. W. W. Beecher, Harr. H. S. Fong, A. Douglas Kinghorn, Danie. M. Brown, Mansuk. C. Wani, Monro. E. Wall, Tin. E. Heiken, Tapa. K. Das Gupta, John M. Pezzuto: Discovery of betulinic acid as a selective inhibitor of human melanoma that functions by induction of apoptosis. Nat. Med. 1, 1046-1051 (1995)
33. Valentin. Zuco, Rosann. Supino, Sabin. C. Righetti, Loredan. Cleris, Edoard. Marchesi, Carl. Gambacorti-Passerini, Franca Formelli: Selective cytotoxicity of betulinic acid on tumor cell lines, but not on normal cells. Cancer Lett. 175:17-25 (2002) (Pubitemid 33153040)
34. Melanie N. Laszczyk: Pentacyclic triterpenes of the lupane, oleanane and ursane group as tools in cancer therapy. Planta Med. 75, 1549-1560 (2009)
35. Alakurtt. Sami, M. kela Tarua, Koskimie. Salmea, Yli-Kauhaluoma Jari: Pharmacological properties of the ubiquitous natural product betulin. Eur. J. Pharm. Sci. 29, 1-13 (2006).
36. U. S. National Institutes of Health: Evaluation of 20% betulinic acid ointment for treatment of dysplastic nevi (moderate to severe dysplasia), 2010. Further information available at: http://www.cancer.gov/search/ ViewClinicalTrials.aspx?cdrid=494341&version=HealthProfessional& protocolsearchid=3664931
37. Georg. R. Pettit, Gordo. M. Cragg, Delber. L. Herald, Jea. M. Schmidt, Prasert Lohavanijaya: Isolation and structure of combretastatin. Can. J. Chem. 60, 1374-1376 (1982)
38. Georg. R. Pettit, She. Bux Singh, Margare. L. Niven, Ernes. Hamel, Jean M. Schmidt: Isolation, structure, and synthesis of combretastatins A-1 and B-1, potent new inhibitors of tubulin assembly, derived from Combretum caffrum. J. Nat. Prod. 50, 119-131 (1987)
39. Scot. L. Young, David J. Chaplin: Combretastatin A4 phosphate: background and current clinical status. Expert. Opin. Invest. Drugs 13, 171-1182 (2004)
40. Dietma. W. Siemann, Davi. J. Chaplin, Patricia A Walicke: A review and update of the current status of the vasculature-disabling agent combretastatin-A4 phosphate (CA4P). Expert. Opin. Investig. Drugs 18, 189-197 (2009)
41. Kevi. G. Pinney, Christophe. Jelinek, Klau. Edvardsen, Davi. J. Chaplin, George R. Pettit: The discovery and development of the combretastatins. In Anticancer Agents from Natural Products, Gordon M. Cragg, David G. I. Kingston and David J. Newman, Eds., CRC Taylor & Francis, Boca Raton, FL, pp. 23-46 (2005)
42. Catherin. M. L. West, Pat Price: Combretastatin A4 phosphate. Anti-Cancer Drugs 5, 179-187 (2004) (Pubitemid 38429409)
43. ClinicalTrials.gov.: Study of Combretastatin and Paclitaxel/Carboplatin in the Treatment of Anaplastic Thyroid Cancer. Further information available at: http://clinicaltrials.gov/ct2/show/NCT00507429 (accessed October 2009).
44. Angel. Delmonte, Cristiana Sessa: AVE8062: a new combretastatin derivative vascular disrupting agent. Expert. Opin. Invest. Drugs 18, 1541-1548 (2009)
45. John W. Lippert III: Vascular disrupting agents. Bioorg. Med. Chem. 5, 605-615 (2007) (Pubitemid 44880701)
46. Gaurisanka. Sa, Tany. Das, Shuvomo. Banerjee, Juni Chakraborty: Curcumin: from exotic spice to modern anticancer drug. Al Ameen J. Med. Sci. 3, 21-37 (2010)
47. Bhara. B. Aggarwal, Chitr. Sundaram, Nikit. Malani, Haruyo Ichikawa: Curcumin: the Indian solid gold. Adv. Exp. Med. Biol. 595, 1-75 (2007)
48. Navnee. Dhillon, Bhara. B. Aggarwal, Rober. A. Newman, Rober. A. Wolff, Ajaikuma. B. Kunnumakkara, Jame. L. Abbruzzese, Chaa. S. Ng, Vladimi. Badmaev, Razelle Kurzrock: Phase II trial of curcumin in patients with advanced pancreatic cancer. Clin. Cancer Res. 14, 4491-4499 (2008)
49. Ala. D. Harmon, Ulric. Weiss, J. V. Silverton: The structure of rohitukine, the main alkaloid of Amoora rohituka (syn. Aphanamixis polystachya) (Meliaceae). Tetrahedron Lett. 20, 721-724 (1979) (Pubitemid 9089392)
50. A. D. Lakdawala, M. V. Shirole, S. S. Mandrekar, A. N. Dohadwalla: Immunopharmacological potential of rohitukine: a novel compound isolated from the plant Dysoxylum binectariferum. Asia Pac. J. Pharmcol. 3, 91-98 (1988)
51. Keit. C. Bible, Scott H. Kaufmann: Flavopiridol: a cytotoxic flavone that induces cell death in noncycling A549 human lung carcinoma cells. Cancer Res. 56, 4856-4861 (1996) (Pubitemid 26374418)
52. Francisc. Arguello, Mar. Alexander, Judit. A. Sterry, Gabriel. Tudor, Eri. M. Smith, Nain. T. Kalavar, John F. Greene Jr., Willia. Koss, C. David Morgan, Sherma. F. Stinson, Timoth. J. Siford, W. Gregory Alvord, Richar. L. Klabansky, Edward A. Sausville: Flavopiridol induces apoptosis of normal lymphoid cells, causes immunosuppression, and has potent antitumor activity in vivo against human leukemia and lymphoma xenografts. Blood 91, 2482-2490 (1998) (Pubitemid 28155524)
53. Adrian M. Senderowicz: Flavopiridol: the first cyclin-dependent kinase inhibitor in human clinical trials. Invest. New Drugs 17, 313-320 (1999) (Pubitemid 30037961)
54. Vladimi. Krystof, Stjepan Uldrijan: Cyclin-dependent kinase inhibitors as anticancer drugs. Curr. Drug Targets 11, 291-302 (2010)
55. Gar. K. Schwartz, Davi. Ilson, Leonar. Saltz, Eilee. O'Reilly, Willia. Tong, Pete. Maslak, Jeanin. Werner, Pa. Perkins, Maxin. Stoltz, David Kelsen: Phase II study of the cyclin-dependent kinase inhibitor flavopiridol administered to patients with advanced gastric carcinoma. J. Clin. Oncol. 19, 1985-1992 (2001) (Pubitemid 32702543)
56. Judit. E. Karp, Amand. Blackford, B. Douglas Smith, Katrin. Alino, Am. Hatfield Seung, Javie. Bolanos-Meade, Jacquelin. M. Greer, Hett. E. Carraway, Steve. D. Gore, Richar. J. Jones, Mar. J. Levis, Michae. A. McDevitt, L. Austin Doyle, John J. Wright: Clinical activity of sequential flavopiridol, cytosine arabinoside, and mitoxantrone for adults with newly diagnosed, poor-risk acute myelogenous leukemia. Leukemia Res. 34, 877-882 (2010)
57. R. G. Powell, D. Weisleder, C. R. Smith Jr: Antitumor alkaloids from Cephalotaxus harringtonia: structure and activity. J. Pharm. Sci. 61, 1227-1230 (1972)
58. Hidej. Itokawa, Xihon. Wang, Kuo-Hsiung Lee: Homoharringtonine and related compounds. In Anticancer Agents from Natural Products, Gordon M. Cragg, David G. I. Kingston and David J. Newman, Eds., CRC/Taylor & Francis, Boca Raton, FL, pp. 47-70 (2005)
59. Alfons. Quintas-Cardama, Hago. Kantarjian, Jorge Cortes: Homoharringtonine, omacetaxine mepesuccinate, and chronic myeloid leukemia circa 2009. Cancer 115, 5382-5393 (2009)
60. The Rocky Mountain Blood and Marrow Transplant Program (RMBMTP), 2009: Initial patients treated in multinational Phase 2/3 study of ceflatonin 09-20-2006. Further information available at: http://www.rockymountainbmt.com/ news/Initial-Patients-T reated-in-Multinational-Phase-23-Study-of-Ceflatonin- 4682.html (accessed October 2009)
61. Alfons. Quintas-Cardama, Jorge Cortes: Omacetaxine mepesuccinate - a semisynthetic formulation of the natural antitumoral alkaloid homoharringtonine, for chronic myelocytic leukemia and other myeloid malignancies. IDrugs 11, 356-372 (2008) (Pubitemid 351677896)
62. Bai-lin Deng: Direct colorimetric method for determination of indigo and indirubin in Qingdai. Zhong Cao Yao 17, 163-164 (1986)
63. Ralp. Hoessel, Sophi. Leclerc, Jan. A. Endicott, Marti. E. M. Nobel, Aliso. Lawrie, Pau. Tunnah, Marys. Leost, Ev. Damiens, Dominiqu. Marie, Dori. Marko, Elle. Niederberger, Weic. Tang, Gerhar. Eisenbrand, Laurent Meijer: Indirubin, the active constituent of a Chinese antileukaemia medicine, inhibits cyclin-dependent kinases. Nat. Cell Biol. 1, 60-67 (1999) (Pubitemid 129495012)
64. Zhijia. Xiao, Yush. Hao, Bingchen. Liu, Lingsheng Qian: Indirubin and meisoindigo in the treatment of chronic myelogenous leukemia in China. Leuk. Lymph. 43, 1763-1768 (2002) (Pubitemid 34874008)
65. Mingxin. Zuo, Ya. Li, Hongb. Wang, Jianhu. Zhou, Hongya. Li, H. Liu, Hongq. Xin, Se. Zhang, Xiaoguo Chen. The antitumor activity of meisoindigo against human colorectal cancer HT-29 cells in vitro and in vivo. J. Chemother. 20, 728-733 (2008)
66. Cooperative Study Group of Phase III Clinical Trial on Meisoindigo. Phase II clinical trial on meisoindigo in the treatment of chronic myelogenous leukemia. Zhonghua Xueyexue Zazhi 18, 69-72 (1997).
67. Kin-Wen. Kong, Hock-En. Khoo, K. Nagendra Prasad, Ami. Ismail, Chin-Pin. Tan, Nor Fadilah Rajab: Revealing the power of the natural red pigment lycopene. Molecules 15, 959-987 (2010)
68. Yoa. Sharoni, Michae. Danilenko, Joseph Levy: Molecular mechanisms for the anticancer activity of the carotenoid lycopene. Drug Dev. Res. 50, 448-456 (2000)
69. V. Bhuvaneswari, S. Nagini: Lycopene: A review of its potential as an anticancer agent. Curr. Med. Chem.-Anti-Cancer Agents 5, 627-635 (2005) (Pubitemid 41601060)
70. U. S. National Institutes of Health: Lycopene in treating patients with metastatic prostate cancer. (2009) http://clinicaltrials.gov/ct2/show/ NCT00068731
71. Eri. Van Quaquebeke, Gentian. Simon, Aureli. Andre, Janiqu. Dewelle, Mohame. El Yazidi, Frederi. Bruyneel, Jerom. Tuti, Odil. Nacoulma, Pierr. Guissou, Christin. Decaestecker, Jean-Claud. Braekman, Rober. Kiss, Francis Darro: Identification of a novel cardenolide (2"-oxovoruscharin) from Calotropis procera and the hemisynthesis of novel derivatives displaying potent in vitro antitumor activities and high in vivo tolerance: structure-activity relationship analyses. J. Med. Chem. 48, 849-856 (2005) (Pubitemid 40209107)
72. Tatjan. Mijatovic, Florenc. Lefranc, Eri. Van Quaquebeke, Fran. Van Vynckt, Franci. Darro, Robert Kiss: UNBS1450: a new hemi-synthetic cardenolide with promising anti-cancer activity. Drug Dev. Res. 68, 164-173 (2007) (Pubitemid 350085801)
73. To. Juncker, Mar. Schumacher, Mari. Dicato, Marc Diederich: UNBS1450 from Calotropis procera as a regulator of signaling pathways involved in proliferation and cell death. Biochem. Pharmacol. 78, 1-10 (2009)
74. Unibioscreen: The piperline - UNBS 1450, 2009. Further information available at http://www.unibioscreen.com/randd/pipeline-unbs1450.html (accessed August 2010)
75. James T. Belanger: Perillyl alcohol: applications in oncology. Altern. Med. Rev. 3, 448-457 (1998) (Pubitemid 128709690)
76. Margare. Barthelman, Weixin. Chen, Hele. L. Gensler, Chuansh. Huang, Zigan. Dong, G. Tim Bowden: Inhibitory effects of perillyl alcohol on UVB - induced murine skin cancer and AP-1 transactivation. Cancer Res. 58, 11-716 (1998)
77. Mari. Lluria-Prevatt, Jeann. Morreale, Jaci. Gregus, Davi. S. Alberts, Fion. Kaper, Amat. Giaccia, Marianne Broome Powell: Effects of perillyl alcohol on melanoma in the TPras mouse model. Cancer Epidemiol. Biomark. Prev. 11, 573-579 (2002) (Pubitemid 34615165)
78. Dea. A. Wiseman, Sea. R. Werner, Pamela L. Crowell: Cell cycle arrest by the isoprenoids perillyl alcohol, geraniol, and farnesol is mediated by p21Cip1 and p27Kip1 in human pancreatic adenocarcinoma cells. J. Pharmacol. Exp. Ther. 320, 1163-1170 (2007) (Pubitemid 46294051)
79. Julian. de Saldanha da Gama Fischer, Paul. Costa Carvalho, An. Gisele da Costa Neves-Ferreira, Clovt. Orlando da Fonseca, Jona. Perales, Mari. da Gloria da Costa Carvalho, Gilberto Barbosa Domont: Anti-thrombin as a prognostic biomarker candidate for patients with recurrent glioblastoma multiform under treatment with perillyl alcohol. J. Exp. Ther. Oncol. 7, 285-290 (2008)
80. Shi-Fe. Chu, Jun-Tian Zhang: New achievements in ginseng research and its future prospects. Chin. J. Integr. Med. 15, 403-408 (2009)
81. Davi. G. Popovich, David D. Kitts: Structure-function relationship exists for ginsenosides in reducing cell proliferation and inducing apoptosis in the human leukemia (THP-1) cell line. Arch. Biochem. Biophys. 406, 1-8 (2002) (Pubitemid 35191710)
82. Gan. Li, Zhenhu. Wang, Yaxua. Sun, K. Liu, Ziren Wang: Ginsenoside 20 (S)-protopanaxadiol inhibits the proliferation and invasion of human fibrosarcoma HT1080 cells. Basic Clin. Pharmacol. Toxicol. 98, 588-592 (2006)
83. Guo-Y. Liu, Xuexia. Bu, Han. Yan, William W.-G. Jia: 20S-Protopanaxadiol- induced programmed cell death in glioma cells through caspase-dependent and -independent pathways. J. Nat. Prod. 70, 259-265 (2007)
84. Jianhu. Sun, Songhu. Hu, Xiaoming Song: Adjuvant effects of protopanaxadiol and protopanaxatriol saponins from ginseng roots on the immune responses to ovalbumin in mice. Vaccine 25, 1114-1120 (2007) (Pubitemid 44937445)
85. X. Ouyang, Z. Yu, Z. Chen, F. Xie, W. Fang, Y. Peng, X. Chen, W. Chen, W. Wang, P. Qi, W. Jia: A pilot study of safety and efficacy of Pandimex with or without paclitaxel in the treatment of advanced solid tumors. J. Clin. Oncol. 23, 3188 (2005)
86. PanaGi. Pharmaceuticals, Inc.: Clinical trials sponsored by pegasus pharmaceuticals group Inc., 2009. Further information available at http://www.panagin.com/clinical.html (accessed Agust 2010)
87. Bhara. B. Aggarwal, Anjan. Bhardwaj, Rish. S. Aggarwal, Navindr. P. Seeram, Shishi. Shishodia, Yasunari Takada: Role of resveratrol in prevention and therapy of cancer: preclinical and clinical studies. Anticancer Res. 24, 2783-2840 (2004) (Pubitemid 39409568)
88. Anupa. Bishayee, Themo. Politis, Altaf S. Darvesh: Resveratrol in the chemoprevention and treatment of hepatocellular carcinoma. Cancer Treat. Rev. 36, 43-53 (2010)
89. Mohamma. Athar, Jun. Ho Back, Xiuwe. Tang, Kwan. Ho Kim, Lev. Kopelovich, Davi. R. Bickers, Arianna L. Kim: Resveratrol: A review of preclinical studies for human cancer prevention. Toxicol. Appl. Pharmacol. 224, 274-283 (2007) (Pubitemid 47575677)
90. Simon. Fulda, Klaus-Michael Debatin: Sensitization for anticancer drug-induced apoptosis by the chemopreventive agent resveratrol. Oncogene 23, 6702.6711 (2004)
91. ClinicalTrials.gov: Resveratrol for patients with colon cancer, 2009. Further information available at: http://clinicaltrials.gov/ct2/show/NCT00256334 (accessed October 2010).
92. Sharnell. S. Phifer, Dongh. Lee, Eun-Kyoun. Seo, Nam-Cheo. Kim, Tyle. N. Graf, Davi. J. Kroll, Herna. A. Navarro, Rober. A. Izydore, Francisc. Jimenez, Ricard. Garcia, Willia. C. Rose, Crai. R. Fairchild, Rober. Wild, Djaj. D. Soejarto, Norma. R. Farnsworth, A. Douglas Kinghorn, Nichola. H. Oberlies, Monro. E. Wall, Mansukh C. Wani: Alvaradoins E-N, antitumor and cytotoxic anthracenone C-glycosides from the leaves of Alvaradoa haitiensis. J. Nat. Prod. 70, 954-961 (2007) (Pubitemid 47056109)
93. Qiuwe. Mi, Danie. Lantvit, Euleni. Reyes-Lim, Heebyun. Chai, Sharnell. S. Phifer, Mansuk. C. Wani, Monro. E. Wall, Ghe. T. Tan, Geoffre. A. Cordell, Norma. R. Farnsworth, A. Douglas Kinghorn, John M. Pezzuto: Apoptotic anticancer effect of alvaradoin E isolated from Alvaradoa haitiensis. Anticancer Res. 779-787 (2005) (Pubitemid 40546844)
94. Iv. J. Curcino Vieira, Raimundo Braz-Felho: Quassinoids. Structural diversity, biological activity and synthetic studies. Stud. Nat. Prod. Chem. 33, Part M, 433-492 (2006)
95. Gordo. M. Gragg, David J. Newman. Plants as a source of anticancer agents. J. Ethnopharmacol. 100, 72-79 (2005)
96. Yoshihid. Usami, Kyok. Nakagawa-Goto, Jing-Y. Lang, Yoo. Kim, Chin-Y. Lai, Masu. Goto, Nobuk. Sakurai, Masahik. Taniguchi, Toshiyuk. Akiyama, Susa. L. Morris-Natschke, Kennet. F. Bastow, Gordo. Cragg, Davi. J. Newman, Mihoy. Fujitakefí, Koich. Takeya, Mien-Chi. Hung, Eva Y.-H. P. Lee, and Kuo-Hsiung Lee: Antitumor Agents. 282. 2'-(R)-O-acetylglaucarubinone, a quassinoid from Odyendyea gabonensis as a potential anti-breast and anti-ovarian cancer agent. J. Nat. Prod. 73, 1553-1558 (2010)
97. Giovann. Ceriotti, Luig. Spandrio, Annibale Gazzaniga: Demonstration, isolation and physical and chemical characteristics of narciclasine, a new antimitotic agent of plant origin. Tumori, 53, 359-371 (1967)
98. Georg. R. Pettit, Venkatswam. Gaddamidi, Gordo. M. Cragg, Delbert L. Herald and Yoneo Sagawa: Isolation and structure of pancratistatin. J. Chem. Soc., Chem. Commun. 1693-1694 (1984) (Pubitemid 15181132)
99. Georg. R. Pettit, Noelee. Melody, Michae. Simpson, Michae. Thompson, Delbert L. Herald, and John C. Knight: Antineoplastic agents 500. Narcistatin. J. Nat. Prod. 66, 92-96 (2003)
100. Patric. Dumont, Lauren. Ingrassia, Sebastie. Rouzeau, Fabric. Ribaucour, Stephani. Thomas, Isabell. Roland, Franci. Darro, Florenc. Lefrancy, Robert Kiss: The Amaryllidaceae isocarbostyril narciclasine induces apoptosis by activation of the death receptor and/or mitochondrial pathways in cancer cells but not in normal fibroblasts. Neoplasia 9, 766-776 (2007) (Pubitemid 47523238)
101. Carl. Griffin, Carolin. Hamm, Jame. McNulty, Siyaram Pandey: Pancratistatin induces apoptosis in clinical leukemia samples with minimal effect on non-cancerous peripheral blood mononuclear cells. Cancer Cell Intern. 10:6 (2010) doi:10.1186/1475-2867-10-6.
102. Pete. Siedlakowski, Amand. McLachlan-Burgess, Carl. Griffin, Sridha. S. Tirumalai, Jame. McNulty, Siyaram Pandey: Synergy of pancratistatin and tamoxifen on breast cancer cells in inducing apoptosis by targeting mitochondria. Cancer Biol. Ther. 7, 376-384 (2008) (Pubitemid 351847051)
103. Georg. R. Pettit, Noelee. Melody, Delbert L. Herald: Antineoplastic agents. 511. Direct phosphorylation of phenpanstatin and pancratistatin. J. Nat. Prod. 67, 322-327 (2004) (Pubitemid 38405689)
104. Xihon. Wang, Susa. L. Morris-Natschke, Kuo-Hsiung Lee: New developments in the chemistry and biology of the bioactive constituents of Tanshen. Med. Res. Rev. 27, 133-148 (2007) (Pubitemid 44975189)
105. Irin. Tsoy Nizamutdinova, Gyeon. Won Lee, Jon. Sil Lee, Mi. Kyung Cho, Ku. Ho Son, S. Jin Jeon, Sa. Sik Kang, Yeon. Shik Kim, Ja. Heun Lee, Ha. Geuk Seo, K. Churl Chang, Hye Jung Kim: Tanshinone I suppresses growth and invasion of human breast cancer cells, MDA-MB-231, through regulation of adhesion molecules. Carcinogenesis 29, 1885-1892 (2008)
106. Jia-Ju. Liu, Wen-D. Liu, Hong-Zh. Yang, Yon. Zhang, Zhi-Gan. Fang, Pei-Qin. Liu, Dong-Ju. Lin, Ruo-Zh. Xiao, Yua. Hu, Chun-Zh. Wang, Xu-Don. Li, Y. He, Ren-Wei Huang: Inactivation of PI3k/Akt signaling pathway and activation of caspase-3 are involved in tanshinone I-induced apoptosis in myeloid leukemia cells in vitro. Ann. Hematol. 89, 1089-1097 (2010)
107. Tai-Lon. Pan, Yu-Chian. Hung, Pei-We. Wang, Shui-Te. Chen, Teng-Kue. Hsu, Nardnis. Sintupisut, Chao-Shen. Cheng, Ping-Chiang Lyu: Functional proteomic and structural insights into molecular targets related to the growth inhibitory effect of tanshinone IIA on HeLa cells. Proteomics 10, 914-929 (2010).
108. X. Yuxian, Tia. Feng, L. Ren, Liu Zhengcai: Tanshinone II-A inhibits invasion and metastasis of human hepatocellular carcinoma cells in vitro and in vivo. Tumori 95, 789-795 (2009)
109. Wenxin. Chen, Ya. Luo, Le. Liu, Hongy. Zhou, Baosha. Xu, Xiuzhe. Han, Ta. Shen, Zhiju. Liu, Yi. Lu, Shile Huang: Cryptotanshinone inhibits cancer cell proliferation by suppressing mammalian target of rapamycin-mediated cyclin D1 expression and Rb phosphorylation. Cancer Prev. Res. 3, 1015-1025 (2010)
110. In-J. Park, Min-Jun. Kim, Oc. Jin Park, Myoun. Gyu Park, Woncha. Choe, Insu. Kang, Sung-So. Kim, Joohun Ha: Cryptotanshinone sensitizes DU145 prostate cancer cells to Fas (APO1/CD95)-mediated apoptosis through Bcl-2 and MAPK regulation. Cancer Lett. 298, 88-98 (2010)
111. Xihon. Wang, Kennet. F. Bastow, Chang-Min. Sun, Yun-Lia. Lin, § Hsi-Jung Yu, Ming-Ja. Don, Tian-Shun. Wu, Seiko. Nakamura, Kuo-Hsiung Lee: Antitumor agents. 239. Isolation, structure elucidation, total synthesis, and anti-breast cancer activity of neo-tanshinlactone from Salvia miltiorrhiza. J. Med. Chem. 47, 5816-5819 (2004) (Pubitemid 39447277)
112. Yizho. Dong, Qia. Shi, Huei-Che. Pai, Chieh-Y. Peng, Shiow-Li. Pan, Che-Min. Teng, Kyok. Nakagawa-Goto, Dongle. Yu, Yi-Na. Liu, Pei-Ch. Wu, Kennet. F. Bastow, Susa. L. Morris-Natschke, Arnol. Brossi, Jing-Y. Lang, Jennife. L. Hsu, Mien-Chi. Hung, Ev. Y.-H. P. Lee, Kuo-Hsiung Lee: Antitumor agents. 272. Structure-activity relationships and in vivo selective anti-breast cancer activity of novel neo-tanshinlactone analogues. J. Med. Chem. 53, 2299-2308 (2010)
113. Ban. Yeon Hwang, Bao-Nin. Su, Heebyun. Chai, Qiuwe. Mi, Leonardu. B. S. Kardono, Joha. J. Afriastini, Soedarson. Riswan, Bernar. D. Santarsiero, Andre. D. Mesecar, Rober. Wild, Crai. R. Fairchild, Gregor. D. Vite, Willia. C. Rose, Norma. R. Farnsworth, Geoffre. A. Cordell, Joh. M. Pezzuto, Steve. M. Swanson, A. Douglas Kinghorn: Silvestrol and episilvestrol, potential anticancer rocaglate derivatives from Aglaia silvestris. J. Org. Chem. 69, 3350-3358, ibid. 6156 (2004) (Pubitemid 38621283)
114. Barbar. Martha Meurer-Grimes, Ji. Yu, Gino Luigi Vairo: Therapeutic compounds and methods. U. S patent 6710075 B2 (2004)
115. Baudoui. Gerard, Regin. Cencic, Jerr. Pelletier, John A. Porco: Enantioselective synthesis of the complex rocaglate (-) - silvestrol. Angew. Chem. Int. Ed. 46, 7831-7834 (2007) (Pubitemid 47612915)
116. Marian. El Sous, Mu. Ling Khoo, Georgin. Holloway, Davi. Owen, Pete. J. Scammells, Mark A. Rizzacasa: Total synthesis of (-)-episilvestrol and (-)-silvestrol. Angew. Chem. Int. Ed. 46, 7835-7838 (2007) (Pubitemid 47612916)
117. Ti. E. Adams, Marian. El Sous, Bil. C. Hawkins, Sebastia. Hirner, Georgin. Holloway, Mu. Ling Khoo, Davi. J. Owen, G. Paul Savage, Pete. J. Scammells, Mark A. Rizzacasa: Total synthesis of the potent anticancer aglaia metabolites (-)-silvestrol and (-)-episilvestrol and the active analogue (-)-4'-desmethoxyepisilvestrol. J. Am. Chem. Soc. 131, 1607-1616 (2009)
118. Qiuwe. Mi, Soyoun. Kim, Ban. Yeon Hwang, Bao-Nin. Su, Heebyun. Chai, Zarem. H. Arbieva, A. Douglas Kinghorn, Steven M. Swanson: Silvestrol regulates G2/M checkpoint genes independent of p53 activity. Anticancer Res. 26, 3349-3356 (2006) (Pubitemid 44701508)
119. Soyoun. Kim, Ban. Yeon Hwang, Bao-Nin. Su, Heebyun. Chai, Qiuwe. Mi, A. Douglas Kinghorn, Rober. Wild, Steven M. Swanson: Silvestrol, a potential anticancer rocaglate derivative from Aglaia foveolata, induces apoptosis in LNCaP cells through the mitochondrial/apoptosome pathway without activation of executioner caspase-3 or -7. Anticancer Res. 27, 2175-2183 (2007). (Pubitemid 47228051)
120. Davi. M. Lucas, Rya. B. Edwards, Gerar. Lozanski, Dere. A. West, Jungoo. D. Shin, Meliss. A. Vargo, Melani. E. Davis, Darlen. M. Rozewski, Am. J. Johnson, Bao-Nin. Su, Virgini. M. Goettl, Nyl. A. Heerema, Thoma. S. Lin, Am. Lehman, Xiaol. Zhang, Davi. Jarjoura, Davi. J. Newman, Joh. C. Byrd, A. Douglas Kinghorn, Michael R. Grever: The novel plant-derived agent silvestrol has B-cell selective activity in chronic lymphocytic leukemia and acute lymphoblastic leukemia in vitro and in vivo. Blood 113, 4656-4666 (2009)
121. Regin. Cencic, Marily. Carrier, Gabriel. Galicia-Vázquez, Marie-Ev. Bordeleau, Ram. Sukarieh, Anni. Bourdeau, Brigitt. Brem, Jos. G. Teodoro, Haral. Greger, Miche. L. Tremblay, John A. Porco Jr., Jerry Pelletier: Antitumor activity and mechanism of action of the cyclopenta[b]benzofuran, silvestrol. PLoS ONE 4, e5223 (2009)
122. Regin. Cencica, Marily. Carriera, Amand. Trnkusa, Joh. A. Porco Jr.b, Mar. Mindenc, Jerry Pelletier. 4Synergistic effect of inhibiting translation initiation in combination with cytotoxic agents in acute myelogenous leukemia cells. Leukemia Res. 34, 535-541 (2010).
123. Marie-Ev. Bordeleau, Franci. Robert, Baudoui. Gerard, Lis. Lindqvist, Samue. M. H. Chen, Hans-Guid. Wende, Brigitt. Brem, Haral. Greger, Scot. W. Lowe, Joh. A. Porco, Jr., Jerry Pelletier: Therapeutic suppression of translation initiation modulates chemosensitivity in a mouse lymphoma model. J. Clin. Invest. 118, 1-11 (2008)
124. Alexande. Kamb, Susa. Wee, Christoph Lengauer: Why is cancer drug discovery so difficult? Nat. Rev. Drug Disc. 6, 115-120 (2007) (Pubitemid 46745339)
125. Lu. Pieters, Arnold J. Vlietinck: Bioguided isolation of pharmacologically active plant components, still a valuable strategy for the finding of new lead compounds? J. Ethnopharmacol. 100, 57-60 (2005) (Pubitemid 41073522)